A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

被引：0

作者：

Mulligan, Stephen P. ^{[1
,2
,3
]}

Gill, Devinder ^{[4
]}

Turner, Paul ^{[5
]}

Renwick, William E. P. ^{[6
]}

Latimer, Maya ^{[7
]}

Mackinlay, Naomi ^{[1
]}

Berkahn, Leanne ^{[8
]}

Simpson, David ^{[9
]}

Campbell, Philip ^{[10
]}

Forsyth, Cecily J. ^{[11
]}

Cull, Gavin ^{[12
]}

Harrup, Rosemary ^{[13
]}

Sulda, Melanie ^{[14
]}

Best, Giles ^{[15
]}

Bressel, Mathias ^{[16
]}

Di Iulio, Juliana ^{[16
]}

Kuss, Bryone J. ^{[14
,17
]}

机构：

[1] Royal N Shore Hosp, Sydney, NSW, Australia

[2] CLL Australian Res Consortium CLLARC, Sydney, NSW, Australia

[3] Australasian Leukaemia & Lymphoma Grp ALLG, Melbourne, Australia

[4] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia

[5] Austin Hosp, Melbourne, Vic 3084, Australia

[6] Royal Melbourne Hosp, Parkville, Vic 3050, Australia

[7] Canberra Hosp, Canberra, ACT, Australia

[8] Auckland Hosp, Auckland, New Zealand

[9] North Shore Hosp, Auckland, New Zealand

[10] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia

[11] Gosford Hosp, Gosford, Australia

[12] Sir Charles Gairdner Hosp, Perth, WA, Australia

[13] Royal Hobart Hosp, Hobart, Tas, Australia

[14] Flinders Med Ctr, Adelaide, SA, Australia

[15] Univ Sydney, Kolling Inst, Sydney, NSW 2006, Australia

[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[17] Flinders Univ S Australia, Adelaide, SA 5001, Australia

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 42 条

[41] Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): Results of a meta-analysis of two phase III trials of the German CLL study group (GCLLSG).
Eichhorst, BF
Busch, R
Wendtner, CM
Hallek, M
BLOOD, 2005, 106 (11) : 213A - 213A
[42] Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101
Lin, Thomas S.
Donohue, Kathleen A.
Byrd, John C.
Lucas, Margaret S.
Hoke, Eva
Bengtson, Elizabeth M.
Atkins, James N.
Link, Brian K.
Rai, Kanti R.
Larson, Richard A.
BLOOD, 2009, 114 (22) : 92 - 92

← 1 2 3 4 5 →